Crossmark Global Holdings Inc. Makes New $328,000 Investment in HUTCHMED (China) Limited (NASDAQ:HCM)

Crossmark Global Holdings Inc. bought a new stake in HUTCHMED (China) Limited (NASDAQ:HCM) in the 3rd quarter, Holdings Channel.com reports. The fund bought 16,792 shares of the company’s stock, valued at approximately $328,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Rhumbline Advisers raised its stake in shares of HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after buying an additional 564 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of HUTCHMED by 9.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock valued at $226,000 after acquiring an additional 1,168 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after purchasing an additional 2,321 shares during the period. Blue Trust Inc. boosted its position in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of HUTCHMED by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company’s stock worth $1,060,000 after purchasing an additional 4,877 shares during the period. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Trading Down 0.7 %

HCM opened at $16.74 on Monday. HUTCHMED has a 12 month low of $11.93 and a 12 month high of $21.92. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The company has a fifty day simple moving average of $18.71 and a 200 day simple moving average of $18.65.

Analysts Set New Price Targets

Several equities analysts have weighed in on HCM shares. StockNews.com raised HUTCHMED from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. The Goldman Sachs Group increased their price target on shares of HUTCHMED from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, August 1st.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.